Website profile

@Twitter

BIOENGINEER.ORG - Bioengineering

  • 3,541articles · 30d
  • 1+ hour agolatest article
  • Aug 14, 2026earliest in window
  • 98%with images
  • 75avg words
articles per day
Categories
  • Science & Nature 2,092
  • Science & Technology 1,941
  • Health & Wellness 1,735
  • Medical 1,355
  • Health 1,171
  • STEM 919
  • Environment 322
  • Food & Drink 253

Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

BIOENGINEER.ORG
bioengineer.org > liquid-biopsy-offers-a-non-invasive-path-to-precision-treatment-for-bladder-cancer

Liquid Biopsy Offers a Non-Invasive Path to Precision Treatment for Bladder

3+ min ago   (81+ words) Bladder cancer remains one of the most challenging malignancies in modern urology, and a newly published comprehensive review in the Journal of Translational Medicine argues that the field is standing at the threshold of a diagnostic revolution. The review, led…...

BIOENGINEER.ORG
bioengineer.org > copper-and-iron-cell-death-pathways-offer-a-new-two-front-attack-on-liver-cancer

Copper and Iron Cell Death Pathways Offer a New Two-Front Attack on Liver

1+ hour, 31+ min ago   (55+ words) Hepatocellular carcinoma, the most common form of primary liver cancer, remains one of the world’s most lethal malignancies, and its treatment options have changed surprisingly little over the past two decades. Now, a review published in Medical Oncology argues that…...

BIOENGINEER.ORG
bioengineer.org > antibody-drug-combination-falls-short-in-first-line-pd-l1-high-metastatic-lung-cancer-trial

Antibody-Drug Combination Falls Short in First-Line PD-L1-High Metastatic

1+ hour, 35+ min ago   (650+ words) A closely watched Phase 3 clinical trial has delivered a sobering verdict on one of the most anticipated treatment strategies in lung cancer medicine....

BIOENGINEER.ORG
bioengineer.org > shifting-identities-how-lung-cancer-cells-change-face-to-outsmart-treatment

Shifting Identities: How Lung Cancer Cells Change Face to Outsmart

1+ hour, 47+ min ago   (69+ words) Small-cell lung cancer has long been one of oncology’s most punishing adversaries. It grows with astonishing speed, spreads early, and presents a treatment paradox that has frustrated clinicians for decades: at diagnosis, tumors melt away under platinum-based chemotherapy, yet relapse…...

BIOENGINEER.ORG
bioengineer.org > more-removed-lymph-nodes-linked-to-worse-outcomes-after-immunotherapy-in-colorectal-cancer

More Removed Lymph Nodes Linked to Worse Outcomes After Immunotherapy in

1+ hour, 50+ min ago   (672+ words) For decades, surgeons have operated on the assumption that when it comes to removing lymph nodes in cancer surgery, more is better. A thorough lymph node dissection has long been considered the gold standard, ensuring accurate staging and reducing the…...

BIOENGINEER.ORG
bioengineer.org > receptor-occupancy-fails-to-predict-immune-activation-in-pembrolizumab-dosing-study

Receptor Occupancy Fails to Predict Immune Activation in Pembrolizumab

1+ hour, 58+ min ago   (55+ words) Pembrolizumab, one of the most widely prescribed cancer immunotherapies in the world, has long been dosed on the assumption that saturating the PD-1 receptor on T cells is the key to unlocking the immune system against tumours. A new translational…...

BIOENGINEER.ORG
bioengineer.org > engineered-t-cell-receptors-with-built-in-icos-deliver-long-lasting-anti-tumor-power

Engineered T Cell Receptors With Built-In ICOS Deliver Long-Lasting

2+ hour, 5+ min ago   (120+ words) Adoptive T cell therapy has delivered striking remissions in some blood cancers, but its promise in solid tumors has been repeatedly undermined by a stubborn problem: the therapeutic cells do not last. Engineered T cells that flood a tumor and…...

BIOENGINEER.ORG
bioengineer.org > scientists-flip-the-drug-discovery-pipeline-to-put-human-biology-first-in-cardiovascular-research

Scientists Flip the Drug Discovery Pipeline to Put Human Biology First in

2+ hour, 9+ min ago   (704+ words) Cardiovascular medicine is quietly undergoing a structural rethink, and the change begins with the order of operations....

BIOENGINEER.ORG
bioengineer.org > income-protects-breast-cancer-survivors-from-heart-disease-unequally-national-study-finds

Income Protects Breast Cancer Survivors From Heart Disease Unequally,

2+ hour, 38+ min ago   (101+ words) Higher income has long been treated as a reliable shield against chronic disease, but a sweeping new analysis of female breast cancer survivors in the United States suggests that this protection is anything but uniform. Drawing on four years of…...

BIOENGINEER.ORG
bioengineer.org > exercise-could-help-cancer-patients-on-immunotherapy-but-nobody-is-telling-them-how

Exercise Could Help Cancer Patients on Immunotherapy, But Nobody Is Telling

2+ hour, 56+ min ago   (55+ words) Immunotherapy has transformed the outlook for people with advanced bladder and kidney cancer. Drugs known as immune checkpoint inhibitors, which block molecular brakes such as CTLA-4, PD-1 and PD-L1 to unleash the immune system against tumours, have dramatically improved long-term…...